Details for New Drug Application (NDA): 062662
✉ Email this page to a colleague
NDA 062662 describes TAZICEF, which is a drug marketed by Hospira and is included in two NDAs. It is available from one supplier. Additional details are available on the TAZICEF profile page.
The generic ingredient in TAZICEF is ceftazidime. There are seventeen drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the ceftazidime profile page.
The generic ingredient in TAZICEF is ceftazidime. There are seventeen drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the ceftazidime profile page.
Summary for 062662
| Tradename: | TAZICEF |
| Applicant: | Hospira |
| Ingredient: | ceftazidime |
| Patents: | 0 |
Suppliers and Packaging for NDA: 062662
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| TAZICEF | ceftazidime | INJECTABLE;INJECTION | 062662 | ANDA | Hospira, Inc. | 0409-5082 | 0409-5082-16 | 25 VIAL in 1 CARTON (0409-5082-16) / 1 INJECTION, POWDER, FOR SOLUTION in 1 VIAL (0409-5082-11) |
| TAZICEF | ceftazidime | INJECTABLE;INJECTION | 062662 | ANDA | Hospira, Inc. | 0409-5084 | 0409-5084-11 | 10 VIAL in 1 CARTON (0409-5084-11) / 1 INJECTION, POWDER, FOR SOLUTION in 1 VIAL (0409-5084-13) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | 500MG/VIAL | ||||
| Approval Date: | Mar 6, 1986 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | 1GM/VIAL | ||||
| Approval Date: | Mar 6, 1986 | TE: | AP | RLD: | No | ||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | 2GM/VIAL | ||||
| Approval Date: | Mar 6, 1986 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
